The report says, though, that the annual rate of growth in the prescription drug spending figure was one of the lowest in more than two decades.
The Canadian Institute for Health Information says the growth in prescription drug spending went up by only 2.3 per cent last year.
It suggests the slowing of the growth of spending on prescription drugs is due to the fact that expired patents on some commonly used drugs have allowed for cheaper generic versions to come on the market.
The report says government policies aimed at lowering drug prices have also had an effect.
Prescribed drugs made up nearly 14 per cent of total health spending in Canada in 2014.
The top 10 classes of drugs accounted for 34 per cent of all prescription drug spending by public drug programs during 2013.
Public programs spent nearly $500 million on a type of medication called anti-TFN drugs, used for rheumatoid arthritis and Crohn's disease.
Rounding out the top five drug classes by spending were: statins to lower cholesterol, proton pump inhibitors for gastric reflux, drugs to treat age-related macular degeneration and drugs for obstructive airway conditions such as asthma, emphysema and chronic bronchitis.
A small proportion of individuals accounted for a large proportion of drug spending for the public programs, the CIHI report shows.
Just under 13 per cent of people accounted for 60.8 per cent of the drug spending in public programs. The report says public drug programs are spending more on high-cost drugs.
The report is based on data from eight provinces — Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta and British Columbia — and one federal program administered by the First Nations and Inuit Health Branch.